Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $26.17

TG Therapeutics, Inc. (NASDAQ:TGTX) has been given an average rating of “Moderate Buy” by the six brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $29.00.

Several brokerages have issued reports on TGTX. JPMorgan Chase & Co. restated an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a research report on Thursday. The Goldman Sachs Group boosted their target price on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. StockNews.com lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of TG Therapeutics in a report on Thursday. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $39.00 price target on shares of TG Therapeutics in a report on Thursday.

Insider Activity at TG Therapeutics

In related news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the sale, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.20% of the stock is owned by company insiders.

Institutional Trading of TG Therapeutics

Hedge funds have recently bought and sold shares of the stock. Pingora Partners LLC purchased a new stake in TG Therapeutics during the fourth quarter worth $27,000. Coppell Advisory Solutions LLC purchased a new stake in TG Therapeutics during the second quarter worth $46,000. Providence Capital Advisors LLC lifted its holdings in TG Therapeutics by 1,403.9% during the first quarter. Providence Capital Advisors LLC now owns 1,910 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,783 shares during the period. KBC Group NV purchased a new stake in TG Therapeutics during the fourth quarter worth $54,000. Finally, PNC Financial Services Group Inc. increased its position in shares of TG Therapeutics by 131.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,014 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 1.2 %

Shares of NASDAQ TGTX opened at $13.99 on Friday. The business’s 50 day moving average is $15.13 and its two-hundred day moving average is $13.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18. TG Therapeutics has a 1-year low of $6.46 and a 1-year high of $35.67. The stock has a market capitalization of $2.16 billion, a P/E ratio of 699.85 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The business had revenue of $43.97 million during the quarter, compared to analyst estimates of $40.06 million. During the same quarter in the previous year, the business earned ($0.39) earnings per share. As a group, research analysts expect that TG Therapeutics will post -0.12 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.